{"id":"https://openalex.org/W2016257631","doi":"https://doi.org/10.1097/01.qai.0000245886.51262.67","title":"Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis","display_name":"Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis","alternate_titles":[],"publication_year":2006,"publication_date":"2006-10-18","ids":{"openalex":"https://openalex.org/W2016257631","doi":"https://doi.org/10.1097/01.qai.0000245886.51262.67","mag":"2016257631","pmid":"https://pubmed.ncbi.nlm.nih.gov/17057609"},"language":"en","primary_location":{"id":"doi:10.1097/01.qai.0000245886.51262.67","doi":"https://doi.org/10.1097/01.qai.0000245886.51262.67","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.qai.0000245886.51262.67","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016257631"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048050447","display_name":"Anton Pozniak","orcid":"https://orcid.org/0000-0002-4091-5323","observed_orcids":["https://orcid.org/0000-0002-4091-5323"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210136304","display_name":"Chelsea and Westminster Hospital","ror":"https://ror.org/038zxea36","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799869770","https://openalex.org/I4210136304"]}],"countries":["GB","US"],"is_corresponding":true,"raw_author_name":"Anton L Pozniak","raw_affiliation_strings":["Chelsea and Westminster Hospital, London, United Kingdom","Bristol-Myers Squibb"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chelsea and Westminster Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I4210136304"]},{"raw_affiliation_string":"Bristol-Myers Squibb","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048477426","display_name":"Joel E. Gallant","orcid":"https://orcid.org/0000-0002-7144-1642","observed_orcids":["https://orcid.org/0000-0002-7144-1642"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel E Gallant","raw_affiliation_strings":["Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD","Bristol Myers Squibb","Johns Hopkins University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"]},{"raw_affiliation_string":"Bristol Myers Squibb","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Johns Hopkins University","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103806974","display_name":"Edwin DeJesus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120784","display_name":"Orlando Immunology Center","ror":"https://ror.org/02cj88v79","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210120784"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin DeJesus","raw_affiliation_strings":["Orlando Immunology Center, Orlando, FL","Orlando Immunology Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orlando Immunology Center, Orlando, FL","institution_ids":["https://openalex.org/I4210120784"]},{"raw_affiliation_string":"Orlando Immunology Center","institution_ids":["https://openalex.org/I4210120784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033023982","display_name":"Jos\u00e9 Ram\u00f3n Arribas","orcid":"https://orcid.org/0000-0002-7410-9450","observed_orcids":["https://orcid.org/0000-0002-7410-9450"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I63634437","display_name":"Universidad Aut\u00f3noma de Madrid","ror":"https://ror.org/01cby8j38","country_code":"ES","type":"education","lineage":["https://openalex.org/I63634437"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Jose R Arribas","raw_affiliation_strings":["Hospital de La Paz, Madrid, Spain","Bristol-Myers Squibb","Universidad Aut\u00f3noma de Madrid"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital de La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]},{"raw_affiliation_string":"Bristol-Myers Squibb","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Universidad Aut\u00f3noma de Madrid","institution_ids":["https://openalex.org/I63634437"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110215411","display_name":"Brian Gazzard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210136304","display_name":"Chelsea and Westminster Hospital","ror":"https://ror.org/038zxea36","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799869770","https://openalex.org/I4210136304"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Brian Gazzard","raw_affiliation_strings":["Chelsea and Westminster Hospital, London, United Kingdom","Chelsea and Westminster Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chelsea and Westminster Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I4210136304"]},{"raw_affiliation_string":"Chelsea and Westminster Hospital","institution_ids":["https://openalex.org/I4210136304"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rafael E Campo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rafael E Campo","raw_affiliation_strings":["University of Miami, Miami, FL","Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Miami, Miami, FL","institution_ids":["https://openalex.org/I145608581"]},{"raw_affiliation_string":"Gilead Sciences","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109168426","display_name":"Shan-Shan Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shan-Shan Chen","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","Gilead Sciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111719543","display_name":"Damian J. McColl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Damian McColl","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","Gilead Sciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074748590","display_name":"Jeffrey Enejosa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Enejosa","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","Gilead Sciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111912277","display_name":"JJ Toole","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John J Toole","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","Gilead Sciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001632717","display_name":"Andrew Cheng","orcid":"https://orcid.org/0000-0002-1121-8051","observed_orcids":["https://orcid.org/0000-0002-1121-8051"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew K Cheng","raw_affiliation_strings":["Gilead Sciences, Foster City, CA","Gilead Sciences, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Inc","institution_ids":["https://openalex.org/I4210140816"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5048050447","https://openalex.org/A5110215411"],"corresponding_institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4210136304"],"apc_list":null,"apc_paid":null,"fwci":16.7157,"has_fulltext":false,"cited_by_count":257,"citation_normalized_percentile":{"value":0.99548967,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"43","issue":"5","first_page":"535","last_page":"540"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tenofovir-disoproxil-fumarate","display_name":"tenofovir disoproxil fumarate","score":0.984000027179718},{"id":"https://openalex.org/keywords/emtricitabine","display_name":"emtricitabine","score":1.0},{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":1.0},{"id":"https://openalex.org/keywords/zidovudine-lamivudine","display_name":"zidovudine/lamivudine","score":0.9359999895095825},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.8600000143051147},{"id":"https://openalex.org/keywords/cd4-count-increase","display_name":"CD4 count increase","score":0.8029999732971191},{"id":"https://openalex.org/keywords/k65r-mutation","display_name":"K65R mutation","score":0.8370000123977661},{"id":"https://openalex.org/keywords/lipodystrophy","display_name":"lipodystrophy","score":0.8149999976158142},{"id":"https://openalex.org/keywords/long-term-treatment-outcomes","display_name":"long-term treatment outcomes","score":0.5019999742507935}],"concepts":[{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.977170467376709},{"id":"https://openalex.org/C2779778239","wikidata":"https://www.wikidata.org/wiki/Q422604","display_name":"Emtricitabine","level":5,"score":0.8791977763175964},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.7938553094863892},{"id":"https://openalex.org/C2779344132","wikidata":"https://www.wikidata.org/wiki/Q155954","display_name":"Tenofovir","level":3,"score":0.7768083810806274},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.6996361017227173},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5160953402519226},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5073885321617126},{"id":"https://openalex.org/C3018457394","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral drug","level":5,"score":0.42514345049858093},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.42089664936065674},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37318626046180725},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.3051595985889435},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.21996405720710754},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.12682509422302246},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.06992053985595703},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000225","descriptor_name":"Adenine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D063065","descriptor_name":"Organophosphonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D063065","descriptor_name":"Organophosphonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D063065","descriptor_name":"Organophosphonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.qai.0000245886.51262.67","doi":"https://doi.org/10.1097/01.qai.0000245886.51262.67","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.qai.0000245886.51262.67","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"pmid:17057609","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17057609","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of acquired immune deficiency syndromes (1999)","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1550111394","https://openalex.org/W2023257490","https://openalex.org/W2042740832","https://openalex.org/W2045131275","https://openalex.org/W2050999867","https://openalex.org/W2055864845","https://openalex.org/W2056779298","https://openalex.org/W2089124181","https://openalex.org/W2109921556","https://openalex.org/W2110937893","https://openalex.org/W2122280827","https://openalex.org/W2165003108","https://openalex.org/W2318289184","https://openalex.org/W4211255637"],"related_works":["https://openalex.org/W2055922999","https://openalex.org/W2110937893","https://openalex.org/W2051815640","https://openalex.org/W2056779298","https://openalex.org/W2049287879","https://openalex.org/W2967678967","https://openalex.org/W2029174775","https://openalex.org/W2135992399","https://openalex.org/W2443834075","https://openalex.org/W2052332986"],"abstract_inverted_index":{"BACKGROUND:":[0],"In":[1,36],"antiretroviral-naive":[2,43],"patients,":[3],"tenofovir":[4],"disoproxil":[5],"fumarate":[6],"(TDF),":[7],"emtricitabine":[8],"(FTC),":[9],"and":[10,22,49,58,98,213,224,232],"efavirenz":[11],"(EFV)":[12],"demonstrated":[13,154],"superior":[14,216],"outcomes":[15],"compared":[16],"with":[17,71],"fixed-dose":[18,218],"zidovudine":[19],"(ZDV)/lamivudine":[20],"(3TC)":[21],"EFV":[23,50,59,96,112,139,152,189,195,214,221],"through":[24,28],"48":[25],"weeks.":[26],"Results":[27],"a":[29,124,155],"96-week":[30],"extension":[31],"phase":[32],"are":[33],"presented.":[34],"METHODS:":[35],"this":[37],"randomized,":[38],"open-label,":[39],"noninferiority":[40],"trial,":[41],"517":[42],"HIV-infected":[44],"patients":[45,70,79,90],"received":[46],"TDF,":[47,211],"FTC,":[48,212],"(TDF":[51],"+":[52,54,61,93,95,109,111,117,136,138,149,151,186,188,194,220],"FTC":[53,94,110,137,150,187],"EFV)":[55],"or":[56],"ZDV/3TC":[57,116,193,219],"(ZDV/3TC":[60],"EFV).":[62],"The":[63,147],"primary":[64],"endpoint":[65],"was":[66,123,180,215],"the":[67,134,172,184,192,208],"proportion":[68],"of":[69,210],"an":[72,100,226,233],"HIV":[73,101,227],"RNA":[74,102,228],"level":[75,103,229],"<400":[76,104,230],"copies/mL":[77,105,132,231],"in":[78,133,159,183,235],"without":[80],"baseline":[81],"nonnucleoside":[82],"resistance.":[83],"RESULTS:":[84],"Through":[85],"week":[86,178],"96,":[87],"significantly":[88,156,181],"more":[89],"receiving":[91,107,115],"TDF":[92,108,135,148,185],"achieved":[97],"maintained":[99],"(75%":[106],"vs.":[113,142,163,198],"62%":[114],"EFV;":[118],"P":[119,144,166,201],"=":[120,145,167],"0.004).":[121],"There":[122],"trend":[125],"toward":[126],"greater":[127,157,182],"virologic":[128],"suppression":[129],"to":[130,217],"<50":[131],"group":[140,153,190,196],"(67%":[141],"61%;":[143],"0.16).":[146],"increase":[158,234],"CD4":[160,236],"count":[161],"(270":[162],"237":[164],"cells/mm;":[165],"0.036).":[168],"No":[169],"patient":[170],"developed":[171],"K65R":[173],"mutation.":[174],"Limb":[175],"fat":[176],"at":[177],"96":[179,206],"versus":[191],"(7.7":[197],"5.5":[199],"kg;":[200],"<":[202],"0.001).":[203],"CONCLUSION:":[204],"Over":[205],"weeks,":[207],"combination":[209],"for":[222],"achieving":[223],"maintaining":[225],"cells.":[237]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016257631","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":18},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":15},{"year":2012,"cited_by_count":24}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
